Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Nivolumab in Leptomeningeal Disease from Solid Tumors
NCT05112549Phase 1Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in leptomeningeal disease (LMD), sponsored by University Hospital Tübingen. Primary endpoint: Dose Limiting Toxicities. Started Oct 2021; status: recruiting.
02
Drugs
03
Conditions
leptomeningeal disease (LMD)
Beyond the preview
Go deeper on NCT05112549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112549.